mitochondrially-driven toxic effects (29). It is known that NRTI triphosphate 83
concentrations exert both antiretroviral and toxic effects, the latter by competitive 84 inhibiting of DNA polymerase γ in vivo (1).This mechanism of toxicity is a 85 selectivity/specificity problem, and therefore toxicity will strongly depend on drug 86 dose and concentration. As such, elevations in NRTI triphosphate concentrations 87 will significantly impact the mitochondrial toxicity of NRTIs. (dTMP), a precursor for DNA synthesis. Therefore, it is a key enzyme of de novo 92 thymidylate synthesis and is responsible for providing thymine nucleotides required 93 for DNA synthesis (24), although TK1 and TK2 recycle deoxythymidine arising from 94
Whole body dual energy X-ray absorptiometry (DEXA) scans (Hologic QDR-4500A 161
Hologic, Inc, 590 Lincoln St, Waltham, MA 02154, USA) were conducted by a 162 single operator on all the patients. The percentage fat at the arms, legs and central 163 abdomen (calculated from the mass of fat versus lean and bone mass) as well as 164 total lean body mass in kilograms was recorded. 165
Definition of HALS and metabolic syndrome 166
The presence or absence of lipoatrophy, lipohypertrophy, and mixed syndrome 167 was determined as previously described (11).The metabolic syndrome was defined 168 according to the U.S. National Cholesterol Education Program (NCEP) Adult 169
Treatment Panel III Guidelines (13) and modified as recommended in the latest 170
American Heart Association/National Heart, Lung, and Blood Institute Scientific 171
Statement (20). Metabolic syndrome was defined as having three or more of the 172
following metabolic risk factors: 1) central obesity (waist circumference ≥ 80 cm in 173 women and ≥ 90 cm in men); 2) hypertriglyceridemia (fasting triglycerides ≥ 1.69 174 mmol/l); 3) low HDL cholesterol (fasting HDL < 1.29 mmol/l in women and < 1.04 175 mmol/l in men); 4) hyperglycemia (fasting glucose ≥ 5.6 mmol/l or already taking 176 oral hypoglycemic agents for treatment of type 2 diabetes); and hypertension 177 (sitting blood pressure ≥ 130/85 mm Hg, taken as mean of two readings taken after 178 rest for at least 10 min, or taking regular antihypertensive medications). 179
Biochemistry laboratory measurements 180
All laboratory investigations were performed after a 12 h overnight fast and at least 181 15 minutes after the placement of a peripheral intravenous catheter. Patients were 182 seated during blood drawing and abstained from smoking at least 15 minutes 183 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from before sampling; tourniquet use was avoided when possible and, if not, was 184 maintained for less than 1 minute. All lipid measurements were performed in a 185
Hitachi 911 system from Roche (Basel, Switzerland). Serum total cholesterol and 186 triglycerides were measured by fully enzymatic standard method and high-density 187 lipoprotein cholesterol by a direct method using polyethylene glycol modified 188 enzymes (PEGME) (45) . Low density lipoprotein (LDL) cholesterol was measured 189 around -80°C pending analysis. The 2 samples were taken 3 hours after dosing (to 204 measure C max ), and the second, 12 hours after dosing (C through ). Our analysis, as 205 pre-specified in the study protocol, was based on C through , and these concentrations 206 spectrometer TSQ Quantum Discovery (Thermo Fisher Scientific, Les Ulis, France) 213 operating in the negative ESI mode for the detection of both d4T-TP and IS (40) . 214
The liquid chromatographic method was used according to a previously published 215 method (41). In these conditions, retention times were around 3.95 and 4.05 min. 216 for d4T-TP and IS, respectively. Amount of d4T-TP was determined in the 217 calibrated range from 50 to 3000 femtomols (fmol) per cell pellet. Finally, the 218
PBMCs of each clinical sample were counted using a validated biochemical test as 219 previously described (4) in order to provide results in fmol/10 6 PBMC. 220
Genotyping analyses 221
The genomic DNA was extracted from the peripheral leucocytes by the salting-out 222 procedure (38). In the TS gene, the variable number tandem repeat (VNTR) of 28 223 bp polymorphism and the G>C SNP in the first and second repeat were analyzed. A 224 DNA fragment was amplified using previously described PCR conditions and 225 primers (11), and directly sequenced using an ABI PRISM 3100 Genetic Analyzer 226 (Applied Biosystems, Foster City, CA, USA). This G to C substitution changes a 227 critical residue in the USF E-box consensus element, abolishes USF-1 binding, and 228 alters transcriptional activity. TS genotypes of the patients were classified according 229 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from to Kawakami and Watanabe into two groups: high expression type (2/3G, 3C/3G 230 and 3G/3G) and low expression type (2/2, 2/3C and 3C/3C) (26). 231
The following polymorphisms in the DHFR gene were analyzed: i) 1610G→T 232 (rs1650694) was determined by direct sequence using an ABI PRISM 3100 Genetic 233
Analyzer (Applied Biosystems, Foster City, CA, USA); ii) a 19bp insertion/deletion 234 using a conventional PCR method (9); iii) a 317A→G (rs408626) substitution, and 235 iv) a 680C→A change. These two polymorphisms were analyzed using Fluidigm's 236 and the 870A→G polymorphism (rs9344) in the CCND1 gene were analyzed using 247 the above described platform based on microfluidic dynamic arrays. 248
Statistical analyses 249
Data are expressed as median with interquartile range (IQR) or as otherwise 250 
Results

264
Population studied 265
Thirty-three Caucasian HIV-1-infected patients, whose ethnicity was traced back to 266 their grandparents, on d4T-based therapy were enrolled. The demographics and 267 viro-immunological status of the population studied is shown in Table 1 . There 268 were no diabetic patients. Only two patients (9.1%) were taking sulphonamides at 269 the time of the study, and none else was taking any other drug except for 270
antiretrovirals. 271
Distribution of genotypes, anthropometric, fat parameters and HALS 272
All 33 patients who fulfilled inclusion criteria were genotyped. With respect to TS 273 genotypes there were 15 patients (45.4%) with high expression genotypes (2/3G, 274 3C/3G, 3G/3G) and 18 patients (54.5%) with low expression genotypes (2/2, 2/3C, 275 Table 3 . 282
Antiretroviral drug exposure and immuno-virological situation 283
Most of the patients (28, 84.8%) had undetectable viral load at the time of the 284 study. The median plasma viral load in the five patients in whom it was detectable, 285 was 215 copies/ml (range: 109-473 copies/ml). 
Intracellular concentrations of d4T-TP and genotypes 290
The mean d4T-TP concentrations were 20. 48 
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There is overwhelming epidemiological evidence linking d4T to the development of 368 fat depot alterations (47). In this regard, our preliminary work that needs further 369 replication, suggests that a genetic mechanism may cause an alteration of 370 nucleotide pools favouring an increase in d4T-TP levels which we have found 371 associated with the development of HALS in two different studies (11). This may 372 explain why TS genotype is also associated with the development of HALS ( Table  373 2). In addition, this mechanism may also explain the different impact of d4T toxicity 374 on fat depots in different individuals, depending on their genetic background. 375
The different genotypes of the VNTR in the TS promoter region (2/2, 2/3, and 3/3) 376 Other enzymes implicated in folate metabolism, and consequently with a potential 393 impact on TS functionalism, are DHFR and RFC1. DHFR is primarily involved in 394 the reduction of dihydrofolate, generated during thymidylate synthesis, to 395 tetrahydrofolate in order to maintain adequate amounts of folate for DNA synthesis 396 and homocysteine remethylation (19). There are a number of polymorphisms of 397 DHFR described. Similarly to MTHFR polymorphisms, none of them significantly 398 modified intracellular d4T-TP levels. RFC1 is an essential folate transporter and 399 functions as a bidirectional anion exchanger, taking up folate cofactors and 400 exporting various organic anions. An 80G→A polymorphism in RFC1 gene has 401 been shown to be associated with alterations in folate and homocysteine 402 metabolism in healthy individuals (9). We found that this genetic variation did not 403 induce substantial modifications in d4T-TP intracellular levels. 404
We also considered the involvement of a biological system that regulates the 405 availability in the cell of two transcription factors (DP-1 and E2F-1) that increase 406 the transcription of among others, the TS, DHFR, and thymidine kinase genes: one 407 of the members of the cyclin family, CCND1, along with cyclin-dependent kinases, 408 phosphorylates and inactivates the retinoblastoma protein and promotes 409 progression through the G1-S phase of the cell cycle. During this process the two 410 mentioned transcription factors are released in the cell. We have found that the 411 G→A polymorphism at nucleotide 870 in the CCND1 gene, which may modulate 412 expression of the Cyclin D1 protein, did not affect the d4T-TP intracellular levels. 413 on July 6, 2017 by guest http://aac.asm.org/
The present cross-sectional study, that includes a limited number of patients, has 414 showed a significant, although preliminary, association between the genotype of 415 the TS gene and d4T-TP intracellular levels in HIV-1-infected patients treated with 416 a d4T-based antiretroviral regime. To our knowledge this is the first 417 pharmacogenetic study that demonstrates the involvement of the metabolic folate 418 pathway in determining the levels of d4T-TP, which in turn have been associated 419 with the appearance of HALS (11). Not unexpectedly, TS genotypes are also 420 associated with the appearance of HALS as well. 
